SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers

Study of the Mechanisms Leading to Increased Hemoglobin Levels and of the Cardiorenal Response in Type 2 Diabetic Patients With Recent Initiation of SGLT2 Inhibitors.

Study of the response to SGLT2 inhibitors in type 2 diabetic patients with relevance to the erythropoesis and indexes of cardiorenal function.

The study enrolls type 2 diabetic patients in whom the introduction of a SGLT2 inhibitor is deemed necessary as part of their routine treatment during their visit to our outpatient diabetes unit.

A whole blood, a serum and a urine sample is obtained before and one month after the initiation of treatment with a SGLT2 inhibitor.

Inclusion Criteria:

• type 2 diabetes
• Hba1C>7% on their current treatment
• introduction of SGLT2 inhibitor as part of their routine care

Exclusion Criteria:

• eGFR<60 ml/min